European Approval for ROMVIMZA™ Provides Major Boost to Deciphera
18.09.2025 - 09:45:05 | boerse-global.deDeciphera Pharmaceuticals has achieved a pivotal regulatory victory with the European Commission granting marketing authorization for its drug ROMVIMZA
. The approval, issued on September 17, 2025, covers the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adult patients for whom surgery is not a viable option. This long-awaited decision represents a transformative milestone for the biotechnology firm, which now operates as part of Ono Pharmaceutical.
The authorization is founded on compelling clinical evidence. Study data demonstrated that after 97 weeks, 23% of patients treated with the drug’s active substance, vimseltinib, achieved a complete response. The trial successfully met its primary endpoints at the 25-week mark, showing statistically significant improvements in range... Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.
